Should Pharma Release IP For COVID-19 Research? Novartis Exec Weighs In
Executive Summary
As World Health Assembly prepares resolution for voluntary pooling and licensing, Novartis global head of IP Corey Salsberg discusses how intellectual property is advancing development of therapeutics and vaccines and the benefits of voluntary rather than compulsory licensing;
You may also be interested in...
EU Politicians Call For Compulsory Licensing, More Joint Procurement For COVID-19
A resolution adopted by the EU’s legislative body includes ways of making Europe more resilient to future pandemics and supply chain risks, and ensuring equitable access to affordable vaccines and medicines. Proposals from the European Parliament to share IP and knowledge have been welcomed by medicines access campaigners.
Global Response To COVID-19 Promises Equitable Access, Independent WHO Probe
A resolution at the latest World Health Assembly meeting on providing universal and equitable access to COVID-19 technologies, medicines and vaccines has been adopted, along with an agreement to review the World Health Organization’s response to the crisis.
Global Response To COVID-19 Promises Equitable Access, Independent WHO Probe
A resolution at the latest World Health Assembly meeting on providing universal and equitable access to COVID-19 technologies, medicines and vaccines has been adopted, along with an agreement to review the World Health Organization’s response to the crisis.